DOCSLIB.ORG

Lung Transplantation a Look Inside a Surgeon's Perspective

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lung Transplantation a Look Inside a Surgeon's Perspective Lung Transplantation A look Inside A Surgeon’s Perspective Hassan Nemeh, MD Henry Ford Hospital Michigan Society of Respiratory Care Spring Conference 2016 Historical background Alexis Carrel 1905 Reported on heart and lung transplant in a cat model Historical background Vladimir Demikhov Reported on 20 different techniques of heart and heart- lung transplant in 1950 Historical background James Hardy, MD First human lung transplant 1964 by Hardy Historical background • Fritz Derom achieved a 10 months survival after lung transplant in a patient with pulmonary silicosis in 1971. Historical background • Bruce Reitz started a clinical trial in heart-lung transplant in 1981 after success in primate model in the lab Historical background • The Toronto group headed by Joel Cooper established lung transplant as we know it today Adult Lung Transplants Number of Transplants by Year and Procedure Type 4000 3893 3745 3750 3500 Bilateral/Double Lung 3450 3177 3000 Single Lung 28382901 2699 2481 2500 2129 2000 19011934 1711 1630 1483 14171440 1500 12961301 1160 1055 1000 874 Number of Transplants 664 500 384 160 5 6 32 69 0 NOTE: This figure includes only the adult lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as representing changes in the 2015 number of adult lung transplants performed worldwide. JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Indications • Cystic fibrosis FEV1 <30%, or clinical worsening • COPD FEV1<25% or PCO2 >55 with pul. HTN • IPF Symptomatic, VC <60-70%, DLCO <50-60% • PPH NYHA class III or IV on vasodilator • Eisenmenger’s NYHA class IIIorIV Adult Lung Transplants Indications (Transplants: January 1995 – June 2014) Diagnosis SLT (N=16,226) BLT (N=29,457) TOTAL (N=45,683) COPD/Emphysema 6,826 (42.1%) 7,856 (26.7%) 14,682 (32.1%) Idiopathic Pulmonary Fibrosis 5,561 (34.3%) 5,442 (18.5%) 11,003 (24.1%) Cystic Fibrosis 228 (1.4%) 7,191 (24.4%) 7,419 (16.2%) Alpha-1 792 (4.9%) 1,667 (5.7%) 2,459 (5.4%) Idiopathic Pulmonary Arterial Hypertension 91 (0.6%) 1,250 (4.2%) 1,341 (2.9%) Pulmonary Fibrosis, Other 758 (4.7%) 1,125 (3.8%) 1,883 (4.1%) Bronchiectasis 65 (0.4%) 1,167 (4.0%) 1,232 (2.7%) Sarcoidosis 301 (1.9%) 857 (2.9%) 1,158 (2.5%) Retransplant: Obliterative Bronchiolitis 338 (2.1%) 440 (1.5%) 778 (1.7%) Connective Tissue Disease 200 (1.2%) 481 (1.6%) 681 (1.5%) Obliterative Bronchiolitis (Not Retransplant) 110 (0.7%) 381 (1.3%) 491 (1.1%) LAM 142 (0.9%) 330 (1.1%) 472 (1.0%) Retransplant: Not Obliterative Bronchiolitis 210 (1.3%) 246 (0.8%) 456 (1.0%) Congenital Heart Disease 93 (0.6%) 333 (1.1%) 426 (0.9%) Cancer 7 (0.0%) 30 (0.1%) 37 (0.1%) Other 504 (3.1%) 661 (2.2%) 1,165 (2.6%) For some retransplants, a diagnosis other than retransplant was 2015 reported, so the total number and percentage of retransplants JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 may be greater. Procedure Type within Indication, by Year by Indication, within Type Procedure Transplants Lung Adult % of Transplants 100% 10% 20% 30% 40% 50% 60% 70% 80% 90% 0% 1999 2001 2003 AT Def 2005 2007 Transplant Lung Bilateral/Double 2009 JHLT. 2015 Oct; 34(10): 1264 34(10): 2015 Oct; JHLT. JHLT. 2011 2013 2014 Oct; 33(10): 1009 33(10): Oct; 2014 1999 2015 2001 COPD 2003 2005 2007 - - 1277 1024 2009 2011 2013 1999 2001 2003 IPF 2005 2007 Single Lung Transplant 2009 2011 2013 1999 2001 2003 IPAH 2005 2007 2009 2011 2013 Adult Lung Transplants Major Indications by Year (Number) 3,500 CF IPF COPD Alpha-1 IPAH Retx 3,000 2,500 2,000 1,500 Number of Transplants 1,000 500 0 Transplant Year For some retransplants, a diagnosis other than 2015 retransplant was reported, so the total percentage of retransplants may be greater. JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Kaplan-Meier Survival by Procedure Type for Primary Transplant Recipients (Transplants: January 1990 – June 2013) 100 Median survival (years): Bilateral/Double lung: 7.1; Conditional=9.7 Single lung: 4.5; Conditional=6.4 80 60 p < 0.0001 40 Survival (%) Survival 20 Bilateral/Double Lung (N=28,135) Single Lung (N=17,099) 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Years 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Kaplan-Meier Survival by Diagnosis (Transplants: January 1990 – June 2013) 100 Alpha-1 (N=2,904) CF (N=7,336) COPD (N=15,064) IPF (N=10,438) IPAH (N=1,584) Sarcoidosis (N=1,136) 80 Median survival (years): Alpha-1=6.5; CF=8.5; COPD=5.5; IPF=4.7; IPAH=5.7; Sarcoidosis=6.1 60 Survival (%) Survival 40 All pair-wise comparisons were significant at p < 0.05 except 20 Alpha-1 vs. IPAH, Alpha-1 vs. Sarcoidosis, COPD vs. IPAH, COPD vs. Sarcoidosis, IPAH vs. Sarcoidosis 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Years 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Functional Status of Surviving Recipients (Follow-ups: January 2009 – June 2014) 100% 10% 20% 80% 30% 40% 60% 50% 60% 40% 70% 80% 20% 90% 100% 0% 1 Year 2 Years 3 Years (N=8,010) (N=6,567) (N=5,446) 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Employment Status of Surviving Recipients (Follow-ups: January 2009 – June 2014) 100% 80% Working (FT/PT Status unknown) Working Part Time 60% Working Full Time 40% Retired Not Working 20% 0% 1 Year 3 Years 5 Years (N=5,408) (N=3,650) (N=2,535) 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Rehospitalization Post Transplant of Surviving Recipients (Follow-ups: January 2009 – June 2014) 100% 80% 60% 40% Hospitalized, Rejection + Infection Hospitalized, Infection Only 20% Hospitalized, Rejection Only Hospitalized, Not Rejection/Not Infection No Hospitalization 0% 1 Year 3 Years 5 Years (N=8,972) (N=6,021) (N=4,199) 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Cumulative Morbidity Rates in Survivors within 1 and 5 Years Post Transplant (Follow-ups: April 1994 – June 2014) Total Total Outcome Within number Within number 1 Year with known 5 Years with known response response Hypertension 51.7% (N=17,813) 80.7% (N=5,293) Renal Dysfunction 22.5% (N=20,551) 53.3% (N=7,056) Abnormal Creatinine ≤ 2.5 mg/dl 15.7% 35.3% Creatinine > 2.5 mg/dl 5.0% 14.3% Chronic Dialysis 1.7% 3.0% Renal Transplant 0.1% 0.8% Hyperlipidemia 26.2% (N=18,510) 57.9% (N=5,643) Diabetes 23.0% (N=20,502) 39.5% (N=6,941) Bronchiolitis Obliterans Syndrome 9.3% (N=19,348) 41.1% (N=5,987) 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Adult Lung Transplants Cumulative Post Transplant Malignancy Rates in Survivors(Follow-ups: April 1994 – June 2014) 1-Year 5-Year 10-Year Malignancy/Type Survivors Survivors Survivors No Malignancy 20,260 (96.3%) 6,191 (83.4%) 1,222 (70.9%) Malignancy (all types combined) 780 (3.7%) 1,234 (16.6%) 501 (29.1%) Malignancy Skin 279 882 359 Type* Lymphoma 272 111 47 Other 200 294 139 Type Not Reported 29 10 2 Other malignancies reported include: adenocarcinoma (2; 2; 1), bladder (2; 1; 0), lung (2; 4; 0), breast (1; 5; 2); prostate (0; 5; 1), cervical (1; 1; 0); liver (1; 1; 1); and colon (1; 1; 0). Numbers in parentheses represent the number of reported cases within each time period. * Recipients may have experienced more than one type of malignancy; therefore, the sum of individual malignancy types may be greater than the total number with malignancy. 2015 JHLT.JHLT. 20152014 Oct;Oct; 34(10):33(10): 12641009--12771024 Future Direction Lung transplant Ex-vivo lung perfusion Ambulatory ECMO Induction of tolerance Bioengineered lung tissue .
Load more

Recommended publications
  • History of Lung Transplantation Akciğer Transplantasyonu Tarihçesi
    REVIEW History of Lung Transplantation Akciğer Transplantasyonu Tarihçesi Gül Dabak Unit of Pulmonology, Kartal Kosuyolu Yüksek Ihtisas Teaching Hospital for Cardiovascular Diseases and Surgery, İstanbul ABSTRACT ÖZET History of lung transplantation in the world dates back to the early 20 Dünyada akciğer transplantasyonu tarihçesi, deneysel çalışmala- th century, continues to the first clinical transplantation performed rın yapılmaya başlandığı 20. yüzyılın ilk yıllarından itibaren Ja- by James Hardy in the United States of America in 1963 and comes mes Hardy’ nin Amerika Birleşik Devletleri’nde 1963’te yaptığı to the present with increased frequency. Over 40.000 heart-lung ilk klinik transplantasyona uzanır ve hızlanarak günümüze gelir. and lung transplantations were carried out in the world up to 2011 yılına kadar dünyada 40,000’in üzerinde kalp-akciğer ve 2011. The number of transplant centers and patients is flourishing akciğer transplantasyonu yapılmıştır. Transplantasyon alanındaki in accordance with the increasing demand and success rate in that artan ihtiyaca ve başarılara paralel olarak transplant merkezleri arena. Lung transplantations that started in Turkey at Sureyyapasa ve hasta sayıları da giderek artmaktadır. Türkiye’de 2009 yılında Teaching Hospital for Pulmonary Diseases and Thoracic Surgery Süreyyapaşa Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma in 2009 are being performed at two centers actively to date. This Hastanesi’ nde başlayan akciğer transplantasyonları günümüzde review covers a general outlook on lung transplantations both in iki merkezde aktif olarak yapılmaktadır. Bu derlemede, ülkemiz- the world and in Turkey with details of the first successful lung deki ilk başarılı akciğer transplantasyonu detaylandırılarak dün- transplantation in our country. yada ve ülkemizdeki akciğer transplantasyonu tarihçesi gözden Keywords: Lung transplantation, heart-lung transplantation, his- geçirilmektedir.
    [Show full text]
  • Historical Perspectives of Lung Transplantation: Connecting the Dots
    4531 Review Article Historical perspectives of lung transplantation: connecting the dots Tanmay S. Panchabhai1, Udit Chaddha2, Kenneth R. McCurry3, Ross M. Bremner1, Atul C. Mehta4 1Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA; 2Department of Pulmonary and Critical Care Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA; 3Department of Cardiothoracic Surgery, Sydell and Arnold Miller Family Heart and Vascular Institute; 4Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA Contributions: (I) Conception and design: TS Panchabhai, AC Mehta; (II) Administrative support: TS Panchabhai, RM Bremner, AC Mehta; (III) Provision of study materials or patients: TS Panchabhai, U Chaddha; (IV) Collection and assembly of data: TS Panchabhai, U Chaddha, AC Mehta; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Atul C. Mehta, MD, FCCP. Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA; Staff Physician, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. Email: [email protected]. Abstract: Lung transplantation is now a treatment option for many patients with end-stage lung disease. Now 55 years since the first human lung transplant, this is a good time to reflect upon the history of lung transplantation, to recognize major milestones in the field, and to learn from others’ unsuccessful transplant experiences. James Hardy was instrumental in developing experimental thoracic transplantation, performing the first human lung transplant in 1963. George Magovern and Adolph Yates carried out the second human lung transplant a few days later.
    [Show full text]
  • HARBIN. NOVEMBER 2017. Sergio
    POWER OVER LIFE AND DEATH Natalie Köhle ARBIN. NOVEMBER 2017. Sergio NESS is NOT in the BRAIN, which seeks HCanavero and Ren Xiaoping 任晓 to prove the existence of an eternal 平 announced that the world’s first hu- soul on the basis of near death experi- man head transplant was ‘imminent’. ence, as well as two guides on seducing They had just completed an eight- women. He also drops flippant refer- een-hour rehearsal on two human ca- ences to Stalin or the Nazi doctor Josef davers, and now claimed to be ready Mengele. for the real deal: the transplant of a human head from a living person with a degenerative disease onto a healthy, but brain-dead, donor body.1 Ren — a US-educated Chinese orthopaedic surgeon, was part of the team that performed the first hand transplant in Louisville in 1999. Canavero, an Italian, and former neu- rosurgeon at the university of Turin, is the more controversial, maverick per- sona of the team. In addition to many respected scientific publications, he Frankenstein’s Monster from The Bride of Frankenstein (1935) published Immortal: Why CONSCIOUS- Source: Commons Wikimedia 276 tor function and sensation. It would 277 also depend on the unproven capacity of the human brain to adjust to — and gain control over — a new body and a new nervous system without suffering debilitating pain or going mad.2 So far, Ren and Canavero have Sergio Canavero transplanted the heads of numerous Source: 诗凯 陆, Flickr lab mice and one monkey, and they Ren and Canavero see the head have also severed and subsequently Power over Life and Death Natalie Köhle transplant, formally known as cepha- mended the spinal cords of several POWER losomatic anastomosis, as the logical dogs.
    [Show full text]
  • Lung Transplantation Adriaan Myburgh
    Lung Transplantation Adriaan Myburgh ! UNIVERSITY OF CAPE TOWN ! Department of Anaesthesia and Perioperative Medicine ! ! ! ! ! ! ! Disclosure Jenna Lowe “ Get me to 21” • 4065 Donors Phalo - URE History • 1947: Vladimir Demikhov performs first successful animal lung transplantation • 1963: James Hardy performs first human lung transplantation in Jackson Mississippi 3 December 1967: First Human heart transplant Denise Darvall to Louis Washkansy • 1986: Joel Cooper performs first successful human double lung transplantation • 2001: Stig Steen performed first successful Non Heart Beating lung transplantation • 2007: Stig Steen performs first ex-vivo reconditioning human lung transplantation Recipients Relative contraindications to lung transplantation • Age > 65 years • Critical or unstable condition (eg, shock, ECMO) • Severely limited functional status • Colonization with highly resistant bacteria, fungi or mycobacteria • Severe obesity (BMI > 30 kg/m2) • Severe osteoporosis • Mechanical ventilation • Other significant medical conditions Orens JB et al. J Heart Lung Transplant 2006; 25: 745-55 Contraindications ? Relative contraindications to lung transplantation • Age > 65 years • Critical or unstable condition (eg, shock, ECMO) • Severely limited functional status • Colonization with highly resistant bacteria, fungi or mycobacteria • Severe obesity (BMI > 30 kg/m2) • Severe osteoporosis • Mechanical ventilation • Other significant medical conditions ECMO Bridge-to-transplant Lung assist device (Novalung®) ECMO Strueber M. Curr Opin Organ
    [Show full text]
  • The Morality of Head Transplant: Frankenstein’S Allegory
    5 THE MORALITY OF HEAD TRANSPLANT: FRANKENSTEIN’S ALLEGORY Aníbal Monasterio Astobiza1 Abstract: In 1970 Robert J. White (1926-2010) tried to transplant the head of a Rhesus monkey into another monkey’s body. He was in- spired by the work of a Russian scientist, Vladimir Demikhov (1916- 1998), who had conducted similar experiments in dogs. Both Demikhov and White have been successful pioneers of organ transplantation, but their scientific attempts to transplant heads of mammals are often remem- bered as infamous. Both scientists encountered important difficulties in such experiments, including their incapacity to link the spinal cord, which ended up by creating quadriplegic animals. In 2013, neurosurgeon Sergio Canavero claimed his capacity and plan to carry out the first human head 1 I am grateful to the Basque Government sponsorship for carrying out a posdoc- toral research fellowship at the Uehiro Centre for Practical Ethics of the University of Oxford, and to the latter institution for its warm welcome. Also, I would like to thank David Rodríguez-Arias for his invaluable comments and suggestions for the improvement of this paper. As usual, any error is solely the author’s responsibility. This work was carried out within the framework of the following research projects: KONTUZ!: “Responsabilidad causal de la comisión por omisión: Una dilucidadión ético-jurídica de los problemas de la acción indebida” (MINECO FFI2014-53926-R); “La constitución del sujeto en la interacción social: identidad, normas y sentido de la acción desde la perspectiva de la filosofía de la acción, la epistemología y la filosofía experimental” (FFI2015-67569-C2-2-P), and “Artificial Intelligence and Biotechnol- ogy of Moral Enhancement Ethical Aspects” (FFI2016-79000-P).
    [Show full text]
  • An Overview of Anesthesia Practices for Heart Transplant in India
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 12 December 2019 Review Article An Overview of Anesthesia Practices for Heart Transplant in India Sandeep Kumar Kar* and Pallav Mishra Assistant Professor, Cardiac Anesthesiology, IPGMER, Kolkata, India *Corresponding Author: Sandeep Kumar Kar, Assistant Professor, Cardiac Anesthesiology, IPGMER, Kolkata, India. Received: November 20, 2019 DOI: 10.31080/ASPS.2019.03.0449 Abstract is growing. Immunosuppressive agents have dramatically improved success of heart transplantation. Non-ischemic cardiomyopathy Heart transplant has seen a significant progress the number of patients with heart failure qualifying for cardiac transplantation has surpassed ischemic cardiomyopathy as need for transplantation. The use of bridge therapy with mechanical circulatory support has improved both short-term and long-term survival of heart transplant recipients has gradually improved over time Keywords: Heart Transplant; Non-Ischemic Cardiomyopathy; Mechanical Circulatory Assist Introduction st Organ Transplantation in India under aegis of National Organi- Dr. Christiaan 1 successful adult heart transplant on Mr. Louis Neethling Washkansky 3 December 1967 at Groote Schuur zation Tissue Transplantation Organization (NOTTO) setup under Barnard hospital Cape town, South Africa Directorate General of Health Services established to oversee all Caves and Transvenous endomyocardial biopsy for diagnosis donation and transplantation activities. In this regard, the entire Colleagues of immune rejection of heart transplant in 1970. country is having the following setup at National, Regional and Jean Francois Immunosuppressive effects of cyclosporin A as State Level. Borel preventive strategy to cardiac rejection in 1976. Bruce Reitz National and Norman 1st successful combined heart lung transplant [4]. (NOTTO) Level Shumway Regional KEM Guwahati Table 2 PGIMER IPGME and RGGGH Level Hospital Medical Chandigarh R Kolkata Chennai (ROTTO) Mumbai College ents.
    [Show full text]
  • To Clinical Xenogeneic Heart Transplantation. Presented at the 15Th Biannual IXA Meeting, Munich, October 11, 2019
    Received: 23 June 2020 | Accepted: 30 July 2020 DOI: 10.1111/xen.12637 REVIEW ARTICLE On the way (my way) to clinical xenogeneic heart transplantation. Presented at the 15th biannual IXA meeting, Munich, October 11, 2019 Bruno Reichart1 | Matthias Längin2 1Transregional Collaborative Research Center 127, Walter Brendel Centre of Experimental Medicine, LMU Munich, Munich, Germany 2Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany Correspondence: Bruno Reichart, Walter Brendel Centre of Experimental Medicine, LMU Munich, Marchioninistraße 27, 81377 Munich, Germany. Email: [email protected] 1 | PRECLINICAL AND At the Ludwig-Maximilians University in Munich, Walter Brendel CLINICAL CONCORDANT HEART (1922-1989) became Head of the Department of Experimental XENOTRANSPLANTATION Surgery (now the “Walter Brendel Center for Experimental Medicine”). During most of the 1960s till the first half of the 1980s, The first heart replacement in humans was a xenograft. On January xenotransplantation remained one of his main interests—and that 23, 1964, James Hardy (1918-2003) from Mississippi, USA, re- of his consultant and chief investigator Claus Hammer (1940-2015). moved the heart of a dying 68-year-old adult and replaced it with The latter characterized preformed natural antibodies (PNABs)4 in the organ of a small chimpanzee. After 90 minutes, the transplant sera of 48 species from seven zoological orders and investigated stopped beating, because it was of course too small.1 Hardy was more than 8300 combinations of serum samples and antigens of heavily criticized by both the public and his medical peers—partly 111 individuals. Among others, his key finding was that PNABs were unfair since he and his team had prepared the intervention care- absent or low between the species within a zoological family (con- fully over years; he should, however, have selected a better first cordant systems) such as domestic dogs, foxes and dingos; domestic recipient.
    [Show full text]
  • "Xenotransplantation". In: Encyclopedia of Life Sciences (ELS)
    Xenotransplantation Introductory article Article Contents David KC Cooper, University of Pittsburgh, Pittsburgh, Pennsylvania, USA . History of Xenotransplantation Mohamed Ezzelarab, University of Pittsburgh, Pittsburgh, Pennsylvania, USA . Need for Xenotransplantation Hidetaka Hara, University of Pittsburgh, Pittsburgh, Pennsylvania, USA . Problems Associated with Rejection of Pig Organs Based in part on the previous version of this Encyclopedia of Life Sciences . Xenotransplantation of Cells (ELS) article, Xenotransplantation by Robert P Lanza and David KC . Problems Associated with Potential Infection Cooper. The Function of Pig Organs in Humans . Other Issues The transplantation of organs and tissues across species boundaries is called xenotransplantation. The most likely source of animal organs and cells for doi: 10.1002/9780470015902.a0001249.pub2 transplantation into humans is the pig. Pigs, therefore, have been genetically engineered to provide their tissues with some protection against the human immune response. However, further immunological barriers need to be overcome. Many questions remain regarding the adequate function of pig organs in humans. The safety of xenotransplantation also remains of some concern. Is there a risk of the transfer of a pig infectious microorganism into the community? Present evidence is that this potential risk is low. This potential, however, has legal and regulatory implications. History of Xenotransplantation went on to transplant occasional chimpanzee or baboon livers in critically ill patients. James Hardy and Leonard The concept of blending parts derived from different spe- Bailey carried out single chimpanzee and baboon heart cies goes back centuries. Centaurs, mermaids and other transplants in patients in 1964 and 1984, respectively. All of creatures from classical mythology come vividly to mind.
    [Show full text]
  • A Contemporary Review of Adult Lung Transplantation and the Portuguese Lung Transplant Program Revised
    MESTRADO INTEGRADO MEDICINA A Contemporary Review of Adult Lung Transplantation and the Portuguese Lung Transplant Program Revised Maria Inês dos Reis Rodrigues M 2019 A Contemporary Review of Adult Lung Transplantation and the Portuguese Lung Transplant Program revised Maria Inês dos Reis Magalhães Rodrigues I [email protected] Mestrado Integrado em Medicina Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto Orientador: Professor Doutor Humberto José da Silva Machado Professor Associado Convidado do Instituto de Ciências Biomédicas Abel Salazar Assistente Hospitalar Graduado Sénior de Anestesiologia do Centro Hospitalar do Porto Diretor do Serviço de Anestesiologia do Centro Hospitalar do Porto Adjunto da Direção Clínica do Centro Hospitalar do Porto Maio 2019 24 de maio de 2019 Agradecimentos Ao Professor Doutor Humberto Machado pela orientação, disponibilidade, interesse e apoio que sempre demonstrou, indispensáveis para a realização do presente trabalho. Aos meus pais e irmã, pelos valores transmitidos e por toda a ajuda e companheirismo ao longo do meu percurso de vida. i Resumo Introdução: O transplante pulmonar é atualmente uma opção terapêutica para doentes com doença pulmonar terminal. Nos últimos 30 anos verificou-se um constante crescimento na área da transplantação pulmonar e, com o desenvolvimento de novos fármacos imunossupressores e o aperfeiçoamento de técnicas cirúrgicas e de conservação de órgãos, houve um aumento da sobrevivência e da qualidade de vida dos doentes transplantados. Em Portugal, o programa de transplantação pulmonar teve início em 2001 no Hospital Santa Marta, Centro Hospitalar de Lisboa Central. Apesar de ser o único centro de transplantação pulmonar do país, um número crescente de transplantes pulmonares tem vindo a ser realizado, passando de 8 transplantes realizados em 2009 para 34 transplantes realizados em 2017.
    [Show full text]
  • Lung Transplant Consideration: Anesthesiologist Perspective
    ISSN: 2693-4965 DOI: 10.33552/OJCR.2020.04.000594 Online Journal of Cardiology Research & Reports Review Article Copyright © All rights are reserved by Sandeep Kumar Kar Lung Transplant Consideration: Anesthesiologist Perspective Sandeep Kumar Kar1* and Pallav Mishra2 Department of Cardiac Anesthesiology, Institute of Post Graduate Medical Education and Research, India *Corresponding author: Sandeep Kumar Kar, Department of Cardiac Received Date: August 07, 2020 Anesthesiology, Institute of Post Graduate Medical Education and Research, Kolkata, India. Published Date: October 21, 2020 Abstract Lung transplant has seen a significant progress since 1963 till this era. Worldwide lung transplant indications have broadened with time. Alpha 1 antitrypsin deficiency used to be the most common reason for transplant but now conditions like idiopathic pulmonary fibrosis, Cystic fibrosis, Non Cystic fibrosis bronchiectasis, lymphangioleiomyomatosis have become leading indications towards lung transplant. Relaxation of donor selection criteria management protocol preserving and optimizing lung function with development ex vivo perfusion techniques to recondition suboptimal lung has improved lung transplantation success. Post-transplant survival still poses challenge as median survival stands low around five years. Keywords: Lung transplant; Donor criteria; Ex vivo; Post-transplant Introduction country is having the following setup at National, Regional and Organ Transplantation in India under aegis of National State Level (Table 1 & 2). Lung transplant be considered for adults Organization Tissue Transplantation Organization (NOTTO) setup with chronic end stage lung disease meeting all of the following under Directorate General of Health Services established to oversee general criteria [5]. all donation and transplantation activities. In this regard, the entire Table 1: History of lung transplant.
    [Show full text]
  • Alternative Therapies for Orthotopic Heart Transplantation
    Alternative Therapies for Orthotopic Heart Transplantation Daniel J. Garry, M.D., Ph.D. Medical Grand Rounds, Department of Internal Medicine July 19, 2001 Disclosure: This is to acknowledge that Daniel Garry, M.D., Ph.D. has not disclosed any financial interests or other relationships with commercial concerns related directly or indirectly to this program. Dr. Garry will be discussing off-label uses in his presentation. BIOGRAPHICAL INFORMATION: Daniel J. Garry, M.D., Ph.D. Assistant Professor, Departments of Internal Medicine, Molecular Biology UT Southwestern Medical Center INTERESTS: Congestive Heart Failure/Cardiac Transplantation Basic science mechanisms·of stem cell biology & oxygen metabolism 2 Congestive heart failure (CHF) Therapeutic strategies for heart failure have evolved tremendously over the past several hundred years. Treatment of congestive heart failure (CHF) or what was referred to as "dropsy" was aimed initially at restoring a balance of fundamental elements and humors. In 1683, Thomas Sydenham recommended bleeding, purges, blistering, garlic and wine. Additional treatments were attempted and abandoned after unrewarding anecdotal experiences (i.e. death). Progress regarding the treatment of heart failure was evident with the introduction of amyl nitrate, mercurial diuretics, digitalis glycosides and bed rest in the early 20th century. Medical therapy for heart failure in the 1960's included digitalis, thiazide diuretics (introduced in 1962) and furosemide (introduced in 1965). The utilization of vasodilators for heart failure were implemented in the 1970's (nitroprusside in 1974 and hydralazine in 1977) and the first large, randomized, clinical trial for heart failure was not completed until 1986 (V-HeFf 1). Since then, the design and completion of a number of large, randomized, placebo-controlled clinical trials have established angiotensin-converting enzyme inhibitors and B-adrenergic receptor antagonists as the cornerstones of therapy.
    [Show full text]
  • Thoracic and Cardiovascular Surgery
    GREAT INSTITUTIONS One Hundred Years of History at Stanford University: Thoracic and Cardiovascular Surgery Y. Joseph Woo, MD, and Bruce A. Reitz, MD The history of thoracic and cardiovascular surgery at Stanford spans a century long period, beginning not long after the founding of Stanford University. Pioneering Stanford surgeons have made landmark discoveries and innovations in pulmonary, transplantation, thoracic aortic, mechanical circulatory support, minimally invasive, valvular, and congenital heart surgery. Fundamental research formed the foundation underlying these and many other advances. Educating and training the subsequent leaders of cardio- thoracic surgery has throughout this century-long history constituted a mission of the highest merit. New Stanford Adult Hospital Semin Thoracic Surg 27:388–397 I 2015 Elsevier Inc. All rights reserved. Central Message Keywords: History, Cardiovascular Surgery, Thoracic Surgery, Transplantation, Aortic Dissection Stanford: Upon a foundation of rigorous scien- tific investigation and dedicated teaching, Stan- ford thoracic and cardiovascular surgeons PRE-STANFORD UNIVERSITY Stanford Faculty in pioneered discoveries and innovations in pul- Lineage tracing of the history of Stanford Cardiothoracic 1914 and led the monary, transplantation, aortic, minimally inva- Surgery could be extended back to 1857, even before the Stanford surgical sive, and congenital heart surgery. founding of Stanford University. Elias Samuel Cooper, a San service at the San Francisco surgeon, authored “Report of an Operation to Francisco General Hospital2 (Fig. 2). Although he practiced a Remove a Foreign Body from Beneath the Heart” published broad spectrum of surgery, much of his clinical and experimental by the San Francisco Medico Chirurgical Association. The work and scholarly publications were in the arena of chest following year in 1858, Cooper founded the first medical surgery.
    [Show full text]